Ho Yeong Lim - Publications, H-index & Citations

Ho Yeong Lim

pochon cha university

78H指数

586论文数

3.9W被引数

收录论文 180

发表时间

Early and Late Survival Dynamics of Immunotherapy Combinations in Advanced HCC: Anchored Indirect Comparison of Atezolizumab plus Bevacizumab versus Durvalumab + Tremelimumab 晚期肝细胞癌免疫疗法联合方案的早期与晚期生存动态：阿替利珠单抗联合贝伐珠单抗与度伐利尤单抗联合特瑞普利单抗的锚定间接比较

European Journal of Cancer

IF7.1

2026-04-21

PREAI

Andrea Casadei-Gardini; Terry Cheuk-Fung Yip; Alessandro Vitale; Federico Rossari; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; José Presa; Gianluca Masi; Changhoon Yoo; Sara Lonardi; Fabio Piscaglia; Takashi Kumada; Mario Scartozzi; Emiliano Tamburini; Francesco Giuseppe Foschi

Integrative multi-omics profiling identifies infiltrative hepatocellular carcinoma as an immunotherapy-resistant subtype with distinct molecular features Lee, W.S.; Woo, S.; Lee, S.H.; Jo, G.H.; Kim, I.; Kim, H.; An, C.; Jung, S.; Kim, G.; Kang, H.; et al. 多组学整合分析鉴定出浸润性HCC为具有独特分子特征且对免疫治疗抵抗的亚型。韩国肝病杂志. 2025; 已接收. [Google Scholar] [CrossRef]

Clinical and Molecular Hepatology

IF16.9

2026-01-01

OAAI

Lee, Won Suk; Woo, Seonjeong; Lee, Sung Hwan; Jo, Gae Hoon; Kim, Ilhwan; Kim, Hyeyeong; An, Chansik; Jung, Sanghoon; Kim, Gwangil; Kang, Haeyoun; Kang, Beodeul; Kim, Jung Sun; Lim, Ho Yeong; Kang, Incheon; Yang, Hannah; Kong, So Jung; Son, Dahyeon; Shin, Dong Jun; Kwon, Woo Young; Lee, Da-Yeon; Lee, Ju-Seog; Park, Junho; Kim, Youngsoo; Hwang, Sohyun; Kim, Chan; Chon, Hong Jae

Outcomes of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC: An International Multicentre Study

LIVER INTERNATIONAL

IF5.2

2025-12-26

OAAI

Kim, Jung Sun; Wong, Jeffrey; Chen, San-chi; Tai, David; Yang, Hannah; Kim, Youngun; Kang, Beodeul; Kim, Ilhwan; Kim, Hyeyeong; An, Chansik; Jang, Su Jin; Kudo, Masatoshi; Lim, Ho Yeong; Kim, Chan; Yau, Thomas; Chon, Hong Jae

Differential implications of tumor endothelial cell and lymphocyte densities in advanced hepatocellular carcinoma patients treated with immunotherapy 肿瘤内皮细胞和淋巴细胞密度在免疫治疗治疗的晚期肝细胞癌患者中的差异意义

npj Precision Oncology

IF8

2025-12-11

OAAI

Gwangil Kim; Beodeul Kang; Jung Yong Hong; Haeyoun Kang; Jung Sun Kim; Sohyun Hwang; Sung Hwan Lee; Sang Hoon Jung; Chansik An; Won Suk Lee; Chiyoon Oum; Gahee Park; Mingu Kang; Yoojoo Lim; Jin Woo Oh; Siraj M. Ali; Chan-Young Ock; Chan Kim; Ho Yeong Lim; Hong Jae Chon

Increased Risk of Young-Onset Pancreatic Cancer Among Adults Aged 20-39 Years with Overweight or Obesity, but Not Underweight: A Nationwide Cohort Study 超重或肥胖但非体重过轻的20-39岁成年人中早发性胰腺癌风险增加：一项全国性队列研究

European Journal of Cancer

IF7.1

2025-11-14

PREAI

Hyun-Jin Kim; Joo-Hyun Park; Jung Yong Hong; Kyungdo Han; Jay J. Shen; Joon Oh Park; Young Suk Park; Ho Yeong Lim

Lenvatinib versus sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: the LEVIATHAN Study 伦伐替尼对比索拉非尼作为阿替利珠单抗联合贝伐珠单抗后肝癌的二线治疗：LEVIATHAN 研究

JHEP Reports

IF7.5

2025-09-23

OAAI

Pasquale Lombardi; Jung Sun Kim; Giulia F. Manfredi; Ciro Celsa; Claudia A.M. Fulgenzi; Antonio D’Alessio; Bernardo Stefanini; Niraj C. Doshi; Emily Warmington; Thomas U. Marron; Matthias Pinter; Bernhard Scheiner; Beodeul Kang; Ho Yeong Lim; Wei-Fan Hsu; Brooke Wietharn; Marianna Silletta; Alessandro Parisi; Chun-Yen Lin; Andrea Dalbeni; Gianluca Masi; Martin Schönlein; Johann von Felden; Fabio Piscaglia; Peter R. Galle; Masatoshi Kudo; Tiziana Pressiani; Lorenza Rimassa; Mario Pirisi; Giuseppe Cabibbo; Hong Jae Chon; David J. Pinato

Comprehensive analysis of KRAS aberrations in pan-cancer, with a focus on prognostic and therapeutic implications 泛癌中KRAS异常的全面分析，重点关注预后和治疗意义

Therapeutic Advances in Medical Oncology

IF4.2

2025-08-17

PREAI

Jaeyun Jung; Jung Yong Hong; Se Hoon Park; Joon Oh Park; Young Suk Park; Ho Yeong Lim; Won Ki Kang; Jeeyun Lee; Sang Yun Ha; Soomin Ahn; Sung Hee Lim; Seung Tae Kim

Prediabetes Remission and the Subsequent Risk of Pancreatic Cancer: A Nationwide Cohort Study 糖尿病前期缓解与后续胰腺癌风险：一项全国性队列研究

American Journal of Preventive Medicine

IF4.5

2025-07-14

PREAI

Joo-Hyun Park; Jung Yong Hong; Kyungdo Han; Jay J. Shen; Minsuk Kwon; Young Suk Park; Joon Oh Park; Ho Yeong Lim

Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population 阿特珠单抗联合贝伐珠单抗与仑伐替尼对比用于巴塞罗那临床肝癌分期B期（BCLC-B）肝细胞癌（HCC）患者：一项真实世界人群研究

Seminars in Oncology

IF2.5

2025-06-09

PREAI

Francesco Vitiello; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; José Presa; Gianluca Masi; Changhoon Yoo; Sara Lonardi; Francesco Tovoli; Takashi Kumada; Mario Scartozzi; Emiliano Tamburini; Francesco Giuseppe Foschi; Mara Persano; Federico Rossari; Silvia Foti; Margherita Rimini

Surgery or chemotherapy first? Unveiling the best approach for colorectal cancer with resectable liver metastasis 手术还是化疗优先？揭示可切除肝转移性结直肠癌的最佳治疗策略

Surgery

IF2.7

2025-06-02

PREAI

Seijong Kim; Jung Kyong Shin; Yoonah Park; Gyu-Seong Choi; Jung Wook Huh; Hee Cheol Kim; Jin Seok Heo; Seong Hyeon Yun; Woo Yong Lee; Seung Tae Kim; Jeeyun Lee; Young Suk Park; Ho Yeong Lim; Yong Beom Cho

[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209-249.[1] Sung H, Ferlay J, Siegel RL, 等. 全球癌症统计数据2020：185个国家36种癌症的全球发病率与死亡率GLOBOCAN估算. CA Cancer J Clin 2021;71:209-249.

JHEP REPORTS

IF7.5

2025-02-01

PREAI

Finn, Richard S.; Gu, Kangsheng; Chen, Xi; Merle, Philippe; Lee, Kyung-Hun; Bouattour, Mohamed; Cao, Peiguo; Wang, Wei; Cheng, Ann-Lii; Zhu, Liangjun; Lim, Ho Yeong; Kudo, Masatoshi; Pan, Yueyin; Chang, Ting-Tsung; Edeline, Julien; Li, Wei; Yang, Ping; Li, Chen; Li, Jianfeng; Siegel, Abby B.; Qin, Shukui

Regorafenib for Hepatocellular Carcinoma in Real-World Practice (REFINE): A Prospective, Observational Study 瑞戈非尼治疗肝细胞癌的真实世界实践（REFINE）：一项前瞻性、观察性研究

LIVER CANCER

IF9.1

2024-12-18

OAAI

Kim, Yoon Jun; Merle, Philippe; Finn, Richard S.; Kudo, Masatoshi; Klumpen, Heinz-Josef; Lim, Ho Yeong; Ikeda, Masafumi; Masi, Gianluca; Gerolami, Rene; Cho, Sung Bum; Hsu, Chih-Hung; Huang, Yi-Hsiang; Jeng, Long-Bin; Kim, Do Young; Lin, Shi-Ming; Pinter, Matthias; Shao, Guoliang; Kato, Naoya; Kurosaki, Masayuki; Numata, Kazushi; Kuo, Kung-Kai; Mao, Yilei; Lin, Yih-Jyh; Zhu, Kangshun; Twumasi-Ankrah, Philip; Khan, Javeed; Awan, Maria; Ozgurdal, Kirhan; Qin, Shukui

Prediabetes persistence or remission and subsequent risk of gallbladder cancer: A nationwide cohort study

EUROPEAN JOURNAL OF CANCER

IF7.1

2024-12-01

PREAI

Park, Joo-Hyun; Hong, Jung Yong; Han, Kyungdo; Park, Young Suk; Park, Joon Oh; Lim, Ho Yeong; Shen, Jay J.

Atezolizumab plus bevacizumab versus lenvatinib for BCLC-B stage of patients with hepatocellular carcinoma: A large real-life worldwide population 阿特珠单抗联合贝伐珠单抗与仑伐替尼治疗BCLC-B期肝细胞癌患者：一项大型真实世界全球人群研究

ANNALS OF ONCOLOGY

IF65.4

2024-12-01

PREAI

Vitiello, F.; Tada, T.; Shimose, S.; Kudo, M.; Cheon, J.; Finkelmeier, F.; Lim, H. Y.; Presa, J.; Masi, G.; Lonardi, S.; Tovoli, F.; Scartozzi, M.; Tamburini, E.; Foschi, F. G.; Persano, M.; Rossari, F.; Foti, S.; Camera, S.; Gardini, A. Casadei; Rimini, M.

TAS-102 (trifluridine/tipiracil) plus bevacizumab versus TAS-102 alone as salvage treatment options for metastatic colorectal cancer in routine clinical practice

FRONTIERS IN ONCOLOGY

IF3.3

2024-09-30

OAAI

Shin, Ji Eun; Lim, Sung Hee; Lee, Jeeyun; Lim, Ho Yeong; Park, Young Suk; Kim, Seung Tae

Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients (P) progressed to atezolizumab plus bevacizumab (AB)仑伐替尼（L）与索拉非尼（S）在进展至阿替利珠单抗联合贝伐珠单抗（AB）方案后的肝细胞癌（HCC）患者（P）中的二线治疗

ANNALS OF ONCOLOGY

IF65.4

2024-09-01

PREAI

Persano, M.; Rimini, M.; Tada, T.; Suda, G.; Shimose, S.; Kudo, M.; Yoo, C.; Cheon, J.; Finkelmeier, F.; Lim, H. Y.; Presa, J.; Rossari, F.; Amadeo, E.; Vitiello, F.; Camera, S.; Foti, S.; Mascia, L.; Scartozzi, M.; Cascinu, S.; Gardini, A. Casadei

Application of tissue and liquid-based next generation sequencing (NGS) for comprehensive genomic profiling: Evaluating the clinical value of ctDNA technology in treatment decision making 组织及液体样本下一代测序(NGS)在全面基因组分型中的应用：评估ctDNA技术在治疗决策中的临床价值

ANNALS OF ONCOLOGY

IF65.4

2024-09-01

PREAI

Usman, F. U.; Sabag, S. Y.; Bhang, E.; Kamali, M.; Pollard, S.; Hussein, A.; Ko-Leong, J.; Hughesman, C.; Alex, D.; Demarco, P.; Weymann, D.; Loree, J. M.; Gill, K.; Wang, Y.; Laskin, J.; Regier, D.; Lim, H.; Chia, S.; Yip, S.; Ho, C.

Fostrox (fostroxacitabine bralpamide) plus lenvatinib in patients with locally advanced unresectable or metastatic hepatocellular carcinoma (HCC) progressed on immunotherapy combinations: Results from a multi-center phase Ib/IIa study Fostrox（fostroxacitabine bralpamide）联合仑伐替尼治疗既往接受免疫联合疗法后进展的局部晚期不可切除或转移性肝细胞癌（HCC）患者：一项多中心 Ib/IIa 期研究的结果

ANNALS OF ONCOLOGY

IF65.4

2024-09-01

PREAI

Chon, H.; Heo, J.; Evans, T. R. J.; Kim, D. Y.; Lim, H. Y.; Macarulla Mercade, T.; Gomez Martin, C.; Moreno Garcia, V.; Ryu, M. H.; Baumann, P.; Bhoi, S.; Jensen, M.; Tunblad, K.; Wallberg, H.; Oberg, F. G.; Reig Monzon, M. E.

Efficacy and safety of bintrafusp alfa in 2 phase I expansion cohorts with advanced HCC

HEPATOLOGY

IF15.8

2024-08-13

PREAI

Lim, Ho Yeong; Heo, Jeong; Peguero, Julio A.; Ryoo, Baek-Yeol; Decaens, Thomas; Barlesi, Fabrice; Moehler, Markus H.; Jehl, Genevieve; Eggleton, S. Peter; Bajars, Marcis; Gulley, James L.

Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients (P) progressed to atezolizumab plus bevacizumab (AB)

ANNALS OF ONCOLOGY

IF65.4

2024-06-01

PREAI

Persano, M.; Rimini, M.; Foti, S.; Camera, S.; Rossari, F.; Amadeo, E.; Vitiello, F.; Tada, T.; Suda, G.; Shimose, S.; Kudo, M.; Yoo, C.; Cheon, J.; Finkelmeier, F.; Lim, H. Y.; Presa, J.; Mascia, L.; Cascinu, S.; Scartozzi, M.; Gardini, A. Casadei

研究方向